Morphological alterations of the hypothalamus in idiopathic intracranial hypertension

Rebecca Kassubek, David Weinstock, Anna Behler, Hans-Peter Müller, Luc Dupuis, Jan Kassubek and Albert C. Ludolph

Abstract

Background: The pathophysiology of idiopathic intracranial hypertension (IIH), a condition characterized by raised intracranial pressure, is not well understood.

Objectives: We hypothesized that the hypothalamus might exhibit alterations in patients with IIH, based on its established association with obesity and the potential role of hormonal and metabolic factors in IIH.

Design: Retrospective single-center cohort study.

Methods: Thirty-three individuals with IIH and 40 matched healthy individuals were studied, including levels of the hormones and proteins leptin, adiponectin, ghrelin, insulin, growth/differentiation factor 15 (GDF15), somatostatin, and melatonin. In vivo high-resolution T1-weighted magnetic resonance imaging (MRI) data were analyzed by quantification of hypothalamic volumes using a well-established segmentation method, separate for the anterior and the posterior hypothalamic subvolumes. An additional analysis was performed using age, gender, and BMI-matched subgroups of 20 IIH patients and 20 controls.

Results: The analysis of laboratory values showed significantly increased insulin, leptin, and melatonin levels for IIH patients in comparison to controls, while adiponectin levels were decreased in IIH; however, only melatonin level differences could be confirmed in the analysis with BMI matching. There was no statistical difference in total hypothalamus volumes between IIH and controls, but the hypothalamic morphology was altered in IIH patients with a lower volume of the anterior part of the hypothalamus and a higher volume of the posterior part; these results were identical in the analysis of the BMI-matched groups. The correlation analyses between hormonal changes and hypothalamic morphology did not achieve significant results.

Conclusion: In this exploratory study, morphological abnormalities of the hypothalamus were observed to be associated with the IIH complex, although the mechanism remains to be unraveled. These findings expand the metabolic phenotype of IIH, but further functional studies are necessary to corroborate these data.

Keywords: hypothalamus, idiopathic intracranial hypertension, magnetic resonance imaging, metabolism, obesity

Introduction

Idiopathic intracranial hypertension (IIH) is a condition characterized by raised intracranial pressure (without hydrocephalus or other causative factors), papilloedema with the potential risk of permanent visual loss, and progressive headache which profoundly reduces the quality of life; international consensus guidelines on diagnostic principles and management were formulated in 2018.1 There is a rising incidence of this disease, and, given that the condition has an established association with obesity, the...
incidence appears related to country-specific prevalences of obesity, mirroring obesity trends. Obese young women in reproductive years are predominantly affected. IIH is a condition of unknown etiology; multiple hypotheses regarding the pathophysiology of this disorder have been presented over the last decades, but there is no consensus. Although the pathophysiology and biochemistry of IIH is poorly understood, a number of factors are currently thought to contribute, including dysregulation of cerebrospinal fluid (CSF) dynamics, raised venous sinus pressure and in particular, the striking association with obesity and female gender have implicated the potential role of hormonal and metabolic factors. In addition, there is evidence that female IIH patients have a unique signature of androgen excess, in the light of an impact of androgens on surrogate markers in CSF secretion. A recent study in 97 female IIH patients provided evidence that IIH can be regarded as a disease of systemic metabolic dysregulation with an insulin- and leptin-resistant phenotype in excess of that driven by obesity.

The hypothalamus plays a crucial role within the complex cortical-subcortical network for the homeostatic regulation of energy balance and metabolic control. Leptin, produced by fat cells and in the hypothalamus, is involved in the regulation of food intake, and early data have shown that a dysregulation of leptin is present in female IIH patients, independent of the body mass index (BMI). In addition, somatostatin, an inhibiting hormone of the hypothalamus within the cascade of growth hormones, could improve IIH symptoms when applied as a synthetic somatostatin-analagon. In the light of this constellation and the strong association with obesity in the majority of patients, an involvement of the hypothalamus in the pathophysiological processes of IIH was hypothesized. There is currently no information available on hypothalamic morphology in patients with IIH. In order to assess the hypothalamic structure, we performed an exploratory study with a magnetic resonance imaging (MRI)-based analysis of hypothalamic volumes, separated for its anterior and posterior fractions, in a group of IIH patients and compared it to healthy controls.

Subjects and methods
In this retrospective single-center cohort study over 10 years, 33 IIH patients and 40 healthy controls were included in total. Because the disease is rare, the sample size is limited to patients who were admitted to our clinic during the study period and met inclusion criteria. IIH patients had to fulfill the standard diagnostic criteria according to Friedman et al. and their adaptation according to Mollan et al., that is, papilloedema, elevated lumbar puncture pressure >25 cm CSF, normal findings in neurological examination and CSF constituents and finally, neuroimaging with normal brain parenchyma and exclusion of cerebral venous thrombosis. Exclusion criteria were the coexistence of any other neurological, metabolic, or infectious disease or other medical condition. The spectrum of clinical symptoms included headache and visual obscuration or blurred vision. In 14 patients, onset of symptoms was a few days to weeks before the MRI, while in 15 patients, the onset of symptoms at the time of the MRI was several months to years ago. In four patients, no reliable data on symptom onset were available. Patients underwent MRI scans at enrolment, together with standardized clinico-neurological and laboratory examinations. Any abnormality in MRI beyond those accepted to be associated with IIH was an exclusion criterion. Blood was sampled under fasting conditions from all subjects, and levels of the following hormones and proteins were quantified from serum by enzyme-linked immunosorbent assay (ELISA) according to standardized procedures: leptin, adiponectin, ghrelin, insulin, growth/differentiation factor 15 (GDF15), somatostatin, and melatonin.

Controls were matched for age and gender. Since IIH is associated with obesity, two age-, gender-, and BMI-matched subgroups were selected from the patients and controls, respectively, and were analyzed separately (Table 1). None of the BMI-matched controls had any radiological signs of IIH.

All participants provided written informed consent for the study protocol according to institutional guidelines which had been approved by the Ethics Committee of Ulm University, Germany (reference #159/17).

MRI acquisition and analysis
MRI data were acquired at a clinical 1.5 T scanner (Siemens Magnetom Symphony) with a standard headcoil. Morphological data were...
obtained using high-resolution T1-weighted magnetization-prepared gradient echo image (MPRAGE) sequence (192 sagittal slices, no gap, 1 mm³ isovoxel, $TE = 43 \text{ ms}$, $TR = 2500 \text{ ms}$). The Tensor Imaging Fiber Tracking Software package, including a volumetric extension package, was used for the landmark-based volumetric analysis of the hypothalamus for IIH patients and controls in a three-step processing pipeline, as previously described.\textsuperscript{13,14} First, a rigid brain normalization preserved the amount of hypothalamic volume. In a second step, spatial up-sampling into a study-specific grid ensured coronal slicing in a common space for all subjects by correcting for individual-based tilt of the head, followed by manual delineation of the left- and right-hemispheric hypothalamus. The hypothalamus was manually delineated using an advanced technique that was based on procedures described by Gabery et al.,\textsuperscript{15} and was described in detail previously.\textsuperscript{13} This delineation procedure is robust and achieves a high level of reproducibility, as
indicated by an intra- and interrater reliability analysis with a coefficient of variation <4% for two raters and an intraclass correlation coefficient between the two raters of \( r > 0.9 \).

To divide the hypothalamus into anterior and posterior part, the criteria reported by Piguet et al.\(^{16}\) were used, that is, given its structural complexity and functional specificity, the hypothalamus was divided into two equal volumes in the anterior–posterior axis. Intracranial volume as a covariate was determined with the Freesurfer image analysis suite (V.6.0.0; http://surfer.nmr.mgh.harvard.edu/), and all reported volumes, that is, the total volume and the volumes for the anterior and posterior hypothalamus, were corrected for intracranial volume.

**Statistics**
Statistical group comparisons were performed using Fisher’s exact test or Wilcoxon–Mann–Whitney \( U \)-test with a Bonferroni-corrected significance level of \( p < 0.004 \). Pearson correlation was used to examine associations between hypothalamic volumes, BMI, and serum levels of leptin, adiponectin, GDF15, and melatonin. Spearman correlation was used to examine associations between hypothalamic volumes, BMI, and serum levels of ghrelin and insulin. The effect size of morphological alterations was calculated as Cohen’s \( d \) which can be interpreted as very small (\( d = 0.1 \)), small (\( d = 0.2 \)), medium (\( d = 0.5 \)), large (\( d = 0.8 \)), very large (\( d = 1.2 \)), or huge effect (\( d = 2.0 \)).\(^{17}\)

**Results**
Clinically, the IIH patient group represented a classical phenotype with a preponderance of women and a significantly higher BMI than controls. Nineteen patients (68.5%) had an empty sella in MRI. The analysis of laboratory values showed significantly increased insulin, leptin, and melatonin levels for IIH patients in comparison to healthy controls (Table 2), while adiponectin levels were decreased in IIH patients. However, the comparison of age, gender, and BMI-matched subgroups only showed a statistically significantly decreased level of melatonin in those patients with IIH (Table 2), while the other hormone levels did not significantly differ between the age, gender, and BMI-matched subgroups.

The total hypothalamic volume was similar in IIH patients and controls as shown in Figure 1(a). Although there was no significant difference between those two groups, there was a tendency toward enlarged hypothalamic volumes in IIH patients. The anterior hypothalamus was reduced in volume in IIH patients (vs controls: –10.9%) with a large effect size of 0.81. In contrast to this lower volume, the volume of the posterior hypothalamus was significantly higher in IIH patients (vs controls: +23.5%) with a very large effect size of 1.40. The comparison of the age, gender, and BMI-matched subgroups of patients and healthy controls [Table 2 and Figure 1(b)] confirmed these findings by also showing a reduction of the anterior hypothalamus (with a large effect size of 1.1) and an enlarged volume of the posterior hypothalamus in patients with IIH (with a very large effect size of 1.41), while the volume of the total hypothalamus did not differ.

The correlation analyses between hormonal serum levels and hypothalamic morphology did not achieve any significant results. There was also no significant correlation between all of the analyzed hormone levels and global, anterior, and posterior hypothalamic volumes. Regarding clinical parameters, there was also no association of any morphological or hormonal parameter with BMI, lumbar puncture pressure, age, or gender. We found no association between medication with topiramate or metformin (which was taken in a subsample of the patients) or presence of an empty sella and hypothalamic volumes as well as between either BMI, age, and gender. Regarding disease duration, there were no differences in hypothalamic volumes between patients with a short duration of disease and patients with a longer duration of disease.

**Discussion**
Since in IIH, increase of BMI often leads to a substantial disease progression, and on the contrary, weight loss is therapeutic, adipose tissue might be one of the major players in IIH.\(^{18,19}\) However, the role of the hypothalamus, as a structure which is crucial in the regulation of the energy balance, has not been investigated in detail in the pathogenesis of IIH. In this pilot study, we hypothesized that, in association with IIH, the morphology of the hypothalamus might exhibit changes in the assessment by \textit{in vivo} MRI, based on the striking association between IIH and
Table 2. Biochemical characteristics and results of hypothalamic volumetric analysis of patients with idiopathic intracranial hypertension (IIH) and healthy control subjects.

|                                | IIH patients (n = 33) | Controls, matched for age and gender (n = 40) | p       |
|--------------------------------|-----------------------|-----------------------------------------------|---------|
| Total hypothalamic volume, mm³ | 915 [791–968]; 681–1197 | 853 [806–905]; 744–969 | n.s.    |
| Anterior hypothalamic volume, mm³ | 451 [382–485]; 261–601 | 480 [452–514]; 415–634 | 0.002   |
| Posterior hypothalamic volume, mm³ | 453 [400–491]; 335–671 | 373 [344–403]; 287–450 | <0.00001 |
| Leptin, ng/ml                   | 32 [14–54]; 2–102     | 9 [4–17]; 1–39 | <0.001 |
| Adiponectin, µg/ml              | 10 [6–21]; 3–69       | 20 [13–38]; 3–79 | 0.002   |
| Ghrelin, pg/ml                  | 97 [<min–639]; < min-3148 | 359 [36–869]; < min-6347 | n.s.    |
| Insulin, µIU/ml                 | 23 [10–45]; < min-97  | 7 [3–11]; < min-35 | <0.001 |
| GDF15, pg/ml                    | 249 [161–431]; 81–820 | 203 [130–254]; 75–773 | n.s.    |
| Melatonin, ng/ml                | 372 [297–391]; 231–613 | 274 [241–293]; 189–367 | <0.001 |
|                                | IIH patients (n = 20) | Controls, matched for age, gender, and BMI (n = 20) | p       |
| Total hypothalamic volume, mm³ | 906 [776–966]; 681–1197 | 850 [811–909]; 744–966 | n.s.    |
| Anterior hypothalamic volume, mm³ | 439 [368–466]; 261–525 | 489 [462–508]; 421–552 | 0.003   |
| Posterior hypothalamic volume, mm³ | 466 [393–511]; 340–671 | 370 [344–403]; 300–422 | <0.001 |
| Leptin, ng/ml                   | 15 [5–34]; 2–78       | 15.5 [5.7–20]; 2–34 | n.s.    |
| Adiponectin, µg/ml              | 10 [6–27]; 3–69       | 16 [10–32]; 3–76 | n.s.    |
| Ghrelin, pg/ml                  | 229 [<min–983]; < min-3148 | 371 [3–581]; < min-6348 | n.s.    |
| Insulin, µIU/ml                 | 23 [9–53]; < min-97   | 7 [3–12]; < min-300 | n.s.    |
| GDF15, pg/ml                    | 249 [210–346]; 81–689 | 216 [148–275]; 75–773 | n.s.    |
| Melatonin, ng/ml                | 365 [317–396]; 249–497 | 271 [241–289]; 131–350 | <0.001 |

BMI, body mass index; GDF15, growth/differentiation factor 15; IIH, idiopathic intracranial hypertension. Values are given in median [interquartile range]; minimum–maximum. Statistical interference between groups was analyzed using Wilcoxon–Mann–Whitney U-test.

obesity and the potential role of hormonal and metabolic factors in IIH pathophysiology, including those regulated *via* the hypothalamus.

As a novel extension of the metabolic IIH phenotype, this study demonstrated the existence of structural hypothalamic abnormalities. There was no statistical difference of hypothalamus size between IIH and non-IIH control individuals with respect to global volumes; however, we observed a lower volume of the anterior part of the hypothalamus of about 11% in IIH patients with a higher volume of the posterior part of about 24%. In order to control for body weight, a comparison with controls matching not only for age and gender but also for BMI was performed, and confirmed these findings by demonstrating a reduction of the anterior hypothalamus and an enlarged volume of the posterior hypothalamus in patients with IIH. It may be safe to conclude that these morphological alterations of the hypothalamus structure are a specific finding associated with IIH, although not presenting as gross volume changes, and might be regarded as a cerebral imaging correlate of pathophysiological processes. Hypothalamic abnormalities have not been
reported yet in the spectrum of IIH-associated findings: neuroimaging is required to demonstrate normal brain parenchyma with no evidence of structural lesions or cerebral venous sinus thrombosis for the diagnosis, while a number of neuroimaging features suggestive of IIH have been reported, including empty sella and alterations of the optic nerve.\textsuperscript{1,5} With respect to the hypothalamus, no consistent structural hypothalamic abnormalities have been established in association with obesity in general, although its involvement in the functional networks of food intake and energy metabolism is beyond all doubt.\textsuperscript{20} A multiparametric MRI study demonstrated a relation between BMI and higher proton diffusivity in the hypothalamus but also not with hypothalamic total volume.\textsuperscript{21} On the contrary, in systemic diseases which are associated with substantial metabolic alterations, body weight loss due to hypermetabolism, and/or reduced food intake has been demonstrated to be associated with hypothalamic atrophy, for example, in neurodegenerative diseases like amyotrophic lateral sclerosis\textsuperscript{13} or Huntington’s disease\textsuperscript{22} and in anorexia nervosa.\textsuperscript{23}

In dementia of the frontotemporal lobar degeneration type, a neurodegenerative disease with symptoms of eating disorder, it could be demonstrated by structural neuroimaging that this disease was associated with atrophy of the hypothalamus which was related to eating behavior; this atrophy was more pronounced posteriorly, that is, in a hypothalamic region containing nuclei that play a critical role in regulating food intake behavior.\textsuperscript{16} Other (diffusion-based) neuroimaging studies in healthy controls demonstrated abnormalities in the anterior–superior hypothalamic subregion which contains the paraventricular nucleus which is suggested to be involved in inhibitory control of food intake and energy expenditure.\textsuperscript{24} In the light of these studies, the current result of abnormal hypothalamic morphology with significantly higher volumes of the posterior hypothalamus than controls might indicate to be a correlate of the involvement in the metabolic control dysregulation. Given that the hypothalamus is anatomically a small, but functionally differentiated area,\textsuperscript{25} the smaller volume of the anterior part which is involved in inhibitory control of food intake and the larger posterior part which is involved in regulating food intake behavior\textsuperscript{16,24} might mirror the altered functional state with respect to structure.

In our study, the metabolic phenotype of IIH could be confirmed with respect to altered hormone levels of leptin, adiponectin, melatonin, and insulin, in accordance with a recent study on metabolic determinants of the IIH phenotype.\textsuperscript{7} Hyperinsulinemia, hyperleptinemia, and low levels of adiponectin suggest general metabolic dysbalance as part of the adipose tissue–insulin

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Alterations in patients with idiopathic intracranial hypertension (IIH) in anterior and posterior hypothalamus volume: (a) comparison of age- and gender-matched patient and control groups and (b) comparison of age-, gender-, and body mass index-matched patient and control groups. Box plots showing the following statistical data: median, the interquartile range and possible outliers. *$p < 0.005$; **$p < 0.00001$.}
\end{figure}
resistance circle. However, in the comparison of subgroups of IIH and controls also matched for BMI, this result did not hold, and the hormone levels did not differ any more except from melatonin levels in IIH. As a consequence, these correlations seem to be based on the BMI differences only and cannot be considered to be an IIH-specific effect. For melatonin, which (among other functions) is suggested to normalize the expression and secretion of leptin and adiponectin, and therefore is thought to have a beneficial role in insulin resistance and maybe even obesity, we observed higher levels in the IIH cohort including the comparison with BMI matching, but its role in IIH needs to be further defined.

Taken together, we found morphological alterations of the hypothalamus in IIH. The observed hypothalamic atrophy could result from tissue remodeling in response or in compensation to the important hormonal changes associated to IIH. Within the metabolic concepts of IIH, it is discussed that IIH represents a distinct neurological manifestation of a phenotype with female androgen excess and male androgen deficiency. Indeed, it is possible that altered androgen metabolism, as observed in IIH, contributes directly to hypothalamic atrophy or indirectly through altered CSF dynamics. In that context, hypogonadism in men is associated with structural hypothalamic defects, and it is possible that the observed altered androgen metabolism in women with IIH contributes to the observed hypothalamic atrophy. Future studies in IIH should include hormones of androgen metabolism together with advanced structural and functional neuroimaging techniques which allow for more detailed differentiation of hypothalamic subunits and target the hypothalamic connectivity.

If a stronger consideration of hypothalamic involvement in the therapeutic concepts of IIH, beyond the approaches with the somatostatin analogon octreotide, might be helpful remains speculative at this stage. It has, however, to be considered that – although the therapeutic impact of weight loss in IIH is clear – the optimal strategy necessary to induce weight loss is not established and may be patient specific, as a combination of the existing approaches (lifestyle and behavioral interventions, bariatric surgery, and novel therapies such as glucagon-like peptide 1 receptor agonists) and further components to be developed in the future.

The findings should be considered in the context of several limitations. First, the sample size was relatively small, but IIH is still regarded as a rare disorder, although it might be underdiagnosed. Second, our imaging approach with T1w structural data and volumetric analysis of the hypothalamus might only be a first indication of abnormalities, but cannot address its functional integration in the pathophysiological concepts. Third, there were no clinical signs of raised intracranial pressure among the controls according to medical history and clinical impression and MRI, but no ophthalmoscopy or lumbar puncture was performed in the control subjects. Finally, future studies will have to use correlational analyses with fluid hormonal markers like leptin, somatostatin, and hormones of androgen metabolism together with advanced structural and functional neuroimaging techniques which allow for more detailed differentiation of hypothalamic subunits and target the hypothalamic connectivity.

In summary, this volumetric analysis of the hypothalamus in IIH patients demonstrated structural abnormalities associated with the IIH-obesity complex, as an extension of the IIH metabolic phenotype. The mechanism of hypothalamic changes remains to be explored. Further studies with higher sample sizes and longitudinal design are necessary to corroborate these pilot data, but it might be useful to integrate the hypothalamus into human research activities and preclinical research in IIH to improve our understanding of the underlying etiology and the mechanistic concepts in driving disease pathology in this burdening disease with the target of effective research programs and well-designed trials in IIH.
Declarations

Ethics approval and consent to participate
All participants provided written informed consent for the study protocol according to institutional guidelines, which the Ethics Committee of Ulm University, Germany had approved (reference #159/17).

Consent for publication
All authors have agreed to the publication of this article.

Author contributions
Rebecca Kassubek: Conceptualization; Data curation; Investigation; Project administration; Writing – original draft.
David Weinstock: Investigation; Visualization; Writing – review & editing.
Anna Behler: Formal analysis; Validation; Visualization; Writing – review & editing.
Hans-Peter Müller: Formal analysis; Methodology; Software; Validation; Writing – review & editing.
Luc Dupuis: Investigation; Validation; Writing – review & editing.
Jan Kassubek: Investigation; Methodology; Validation; Writing – original draft.
Albert C. Ludolph: Conceptualization; Project administration; Supervision; Writing – review & editing.

Acknowledgements
None.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Competing interests
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JK is an Associate Editor of Therapeutic Advances in Chronic Disease and an author of this paper; therefore, the peer-review process was managed by alternative members of the board and the submitting editor had no involvement in the decision-making process. No further conflicts of interest are to report for all authors.

Availability of data and materials
Data are available upon reasonable request. Reasonable data-sharing requests are made in writing through Rebecca Kassubek (rebecca.kassubek@uni-ulm.de) and require a formal data-sharing agreement. Data sharing agreements must include details on how the data will be stored, who will have access to the data and the intended use of the data, and agreements as to the allocation of intellectual property.

ORCID iDs
Rebecca Kassubek https://orcid.org/0000-0001-5384-7334
Jan Kassubek https://orcid.org/0000-0002-7106-9270

References
1. Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry 2018; 89: 1088–1100.
2. Mitchell JL, Mollan SP, Vijay V, et al. Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension. Curr Opin Neurol 2019; 32: 422–431.
3. Mollan SP, Aguiar M, Evison F, et al. The expanding burden of idiopathic intracranial hypertension. Eye 2019; 33: 478–485.
4. Biousse V, Bruce BB and Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83: 488–494.
5. Wang MTM, Bhatti MT and Danesh-Meyer HV. Idiopathic intracranial hypertension: pathophysiology, diagnosis and management. J Clin Neurosci 2022; 95: 172–179.
6. O’Reilly MW, Westgate CSJ, Hornby C, et al. A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight 2019; 4: e125348.
7. Westgate CS, Botfield HF, Alimajstorovic Z, et al. Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight 2021; 6: 145346.
8. Berthoud H-R. Interactions between the ‘cognitive’ and ‘metabolic’ brain in the control of food intake. Physiol Behav 2007; 91: 486–498.
9. Lampl Y, Eshel Y, Kessler A, et al. Serum leptin level in women with idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2002; 72: 642–643.

10. Panagopoulos GN, Deftereos SN, Tagaris GA, et al. Octreotide: a therapeutic option for idiopathic intracranial hypertension. Neurou Neurophysiol Neurosci 2007; 1, https://pubmed.ncbi.nlm.nih.gov/17700925/.

11. Friedman DI, Liu GT and Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013; 81: 1159–1165.

12. Müller H-P, Unrath A, Ludolph AC, et al. Preservation of diffusion tensor properties during spatial normalization by use of tensor imaging and fibre tracking on a normal brain database. Phys Med Biol 2007; 52: N99–N109.

13. Gorges M, Vercruysse P, Müller H-P, et al. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2017; 88: 1033–1041.

14. Gorges M, Kuntz B, Del Tredici K, et al. Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson’s disease. Mov Disord 2019; 34: 1566–1570.

15. Gabery S, Georgiou-Karistianis N, Lundh SH, et al. Volumetric analysis of the hypothalamus in Huntington disease using 3T MRI: the IMAGE-HD study. PLoS ONE 2015; 10: e0117593.

16. Piguet O, Petersén Ā, Yin Ka, Lam B, et al. Eating and hypothalamic changes in behavioral-variant frontotemporal dementia. Ann Neurol 2011; 69: 312–319.

17. Sawilowsky SS. New effect size rules of thumb. J Mod App Stat Meth 2009; 8: 597–599.

18. Hornby C, Mollan SP, Botfield H, et al. Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuroophthalmol 2018; 38: 522–530.

19. Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341: c2701.

20. Lizarbe B, Campillo B, Guadilla I, et al. Magnetic resonance assessment of the cerebral alterations associated with obesity development. J Cereb Blood Flow Metab 2020; 40: 2135–2151.

21. Thomas K, Beyer F, Lewe G, et al. Higher body mass index is linked to altered hypothalamic microstructure. Sci Rep 2019; 9: 17373.

22. Cheong RY, Gabery S and Petersén Ā. The role of hypothalamic pathology for non-motor features of Huntington’s disease. J Huntington Dis 2019; 8: 375–391.

23. Roger C, Lasbleiz A, Guye M, et al. The role of the human hypothalamus in food intake networks: an MRI perspective. Front Nutr 2021; 8: 760914.

24. Spindler M, Özyurt J and Thiel CM. Automated diffusion-based parcellation of the hypothalamus reveals subunit-specific associations with obesity. Sci Rep 2020; 10: 22238.

25. Carrell S, Gibson C, Benson L, et al. Neuroimaging and obesity: current knowledge and future directions. Obes Rev 2012; 13: 43–56.

26. Khanna D, Khanna S, Khanna P, et al. Obesity: a chronic low-grade inflammation and its markers. Curr Rev 14: e22271.

27. Guan Q, Wang Z, Cao J, et al. Mechanisms of melatonin in obesity: a review. Int J Mol Sci 2021; 23: 218.

28. Berkseth KE, Rubinow KB, Melhorn SJ, et al. Hypothalamic gliosis by MRI and visceral fat mass negatively correlate with plasma testosterone concentrations in healthy men: hypothalamic gliosis and testosterone in men. Obesity 2018; 26: 1898–1904.

29. Capriani S, Todisco T, Ghiandai N, et al. Biochemical predictors of structural hypothalamus–pituitary abnormalities detected by magnetic resonance imaging in men with secondary hypogonadism. J Endocrinol Invest 2021; 44: 2785–2797.

30. House PM and Stodieck SR. Octreotide: the IIH therapy beyond weight loss, carbonic anhydrase inhibitors, lumbar punctures and surgical/interventional treatments. Clin Neurol Neurosurg 2016; 150: 181–184.

31. Mollan SP, Tahranii AA and Sinclair AJ. The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight. Neurol Clin Pract 2021; 11: e504–e507.

32. Grech O, Mollan SP, Wakerley BR, et al. Emerging themes in idiopathic intracranial hypertension. J Neurol 2020; 267: 3776–3784.
33. Schönknecht P, Anwander A, Petzold F, et al. Diffusion imaging-based subdivision of the human hypothalamus: a magnetic resonance study with clinical implications. *Eur Arch Psychiatry Clin Neurosci* 2013; 263: 497–508.

34. Kullmann S, Heni M, Linder K, et al. Resting-state functional connectivity of the human hypothalamus. *Hum Brain Mapp* 2014; 35: 6088–6096.

35. Almajstorovic Z, Westgate CSJ, Jensen RH, et al. Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. *Eye* 2020; 34: 1321–1333.